Testing furmonertinib with chemotherapy for EGFR lung cancer that has spread to the brain
Original title: A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late-stage study, but it is still a test and not approved care.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study compares two drug plans for lung cancer that has spread to the brain.
Who this trial is for. This trial is for people with non-squamous non-small cell lung cancer that has an EGFR mutation and has spread to the brain. One group takes furmonertinib plus platinum-based chemotherapy, another takes osimertinib alone, and a smaller group takes furmonertinib alone.
Where it stands. The trial has not reported results. It is measuring how well each drug plan works and how safe it is. The first part enrolls about 30 people to check the safety of two furmonertinib doses, 80 mg and 160 mg. The larger part plans to enroll about 350 people. The answers are not in yet.
What this means, and what it doesn't
What it could mean: This is a large late-stage study of drugs that are already being tested in people. If your lung cancer has an EGFR mutation and has spread to your brain, you could ask your care team whether a trial like this fits you. They can explain the possible risks and what taking part would involve.
What it doesn't mean: This does not mean these drugs are proven to work better. A trial is a test, not care your own doctor can give you yet. Joining a study is not a promise that it will help you. It is not a cure, and no one can say yet which drug plan is better.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.